Retrophin to Present at Upcoming Investor Conferences SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming investor conferences in February and March:...

Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2019 SAN DIEGO, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from the Phase 2 DUET Study examining the impact of sparsentan on quality of...

Retrophin Announces Appointment of Peter Heerma as Chief Commercial Officer SAN DIEGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the appointment of Peter Heerma as chief commercial officer, effective immediately. In this newly created...

Retrophin Reports Fourth Quarter and Full Year 2018 Financial Results Top-line results from pivotal Phase 3 FORT Study in PKAN expected in 3Q 2019 Two pivotal Phase 3 studies of sparsentan progressing on-track to enable potential first-in-class treatment for both FSGS...

Retrophin to Present at the 8th Annual SVB Leerink Global Healthcare Conference SAN DIEGO, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the 8th Annual SVB Leerink Global...